Brian C Stephenson

FTH CFO Brian C Stephenson buys 17,413 shares in 8 transactions for $405,920.62 post-IPO

Brian C Stephenson, who was CFO at the time, purchased 17,413 shares across 8 separate transactions on 2026-06-22 and 2026-06-23 for a combined $405,920.62, establishing an initial stake in Faeth Therapeutics following its recent listing 6 trading days prior. The purchases occurred at prices ranging from $20.23 to $25.91, with a blended average price of $23.31, and the current price stands at $24.54. This acquisition is noteworthy given the company's fundamental profile: Faeth reported net income of $-170,236,000.00 for its most recent full fiscal year, with a current market cap of $32,931,232.14, indicating the company is unprofitable. The pattern of multiple purchases at varying prices over two consecutive days during the early post-IPO phase warrants investor attention given the company's negative earnings backdrop.

CFO Brian C Stephenson sold 68,000 BBIO shares at $36.29 on 2025-01-28, reducing holdings 42.0% to 93.8K shares ($2.5M transaction).

Brian C Stephenson, Secretary, Treasurer & CFO of BridgeBio Pharma, executed a substantial sale of 68,000 shares (42.0% reduction in his pre-transaction holdings) on 2025-01-28 at $36.29 per share. The transaction occurred during a period of significant upward price momentum: the stock is up 31.1% over 30 days and 41.2% over 90 days, trading 8.3% below its 52-week high of $39.23. However, BridgeBio faces severe operational headwinds: the company reported negative net income of -$164.3M, annual revenue contracted 88.0% year-over-year, and the latest quarterly revenue stands at only $2.7M against a $6.8B market capitalization. Stephenson's prior sales at BBIO have generated a 0% well-timed rate at the 90-day mark (0 of 4 prior sells produced declines after sale), suggesting his historical timing at this ticker has not preceded stock weakness. The magnitude of the holdings reduction combined with BBIO's deteriorating financial profile and modest revenue base warrant close attention to forthcoming operational updates.